Authors/National Vaccine Advisory Committee: Georges Peter, MD (chair), Brown Medical School, Providence, RI; Ann Margaret Arvin, MD, Stanford University School of Medicine, Stanford, Calif; Jeffrey P. Davis, MD, Wisconsin Division of Health, Madison, Wis; Michael D. Decker, MD, MPH, Aventis Pasteur, Swiftwater, Pa; Patricia Fast, MD, PhD, International AIDS Vaccine Initiative, New York, NY; Fernando A. Guerra, MD, MPH, San Antonio Metropolitan Health District, San Antonio, Tex; Charles M. Helms, MD, PhD, University of Iowa Hospital and Clinics, Iowa City; Alan Richard Hinman, MD, Task Force for Child Survival and Development, Decatur, Ga; Ruth Katz, JD, MPH, George Washington University School of Public Health and Health Services, Washington, DC; Jerome O. Klein, MD, Boston Medical Center, Boston, Mass; Mary Beth Koslap-Petraco, MS, CPNP, Suffolk County Department of Health Services, Lindenhurst, NY; Peter R. Paradiso, PhD, Wyeth Vaccines, Henrietta, NY; William Schaffner, MD, Vanderbilt University School of Medicine, Nashville, Tenn; Patricia N. Whitley-Williams, MD, Robert Wood Johnson Medical School, New Brunswick, NJ; Donald E. Williamson, MD, Alabama Department of Public Health, Montgomery; and Bruce Gellin, MD, executive secretary of NVAC, Washington, DC.
Between late 2000 and the spring of 2003, the United States experienced
shortages of vaccines against 8 of 11 preventable diseases in children. In
response, the Department of Health and Human Services requested that the National
Vaccine Advisory Committee (NVAC) make recommendations on strengthening the
supply of routinely recommended vaccines. The NVAC appointed a Working Group
to identify potential causes of vaccine supply shortages, develop strategies
to alleviate or prevent shortages, and enlist stakeholders to consider the
applicability and feasibility of these strategies. The NVAC concluded that
supply disruptions are likely to continue to occur. Strategies to be implemented
in the immediate future include expansion of vaccine stockpiles, increased
support for regulatory agencies, maintenance and strengthening of liability
protections, improved communication among stakeholders, increased availability
of public information, and a campaign to emphasize the benefits of vaccination.
Strategies requiring further study include evaluation of appropriate financial
incentives to manufacturers and streamlining the regulatory process without
compromising safety or efficacy.
National Vaccine Advisory Committee. Strengthening the Supply of Routinely Recommended Vaccines in the United StatesRecommendations From the National Vaccine Advisory Committee. JAMA. 2003;290(23):3122-3128. doi:10.1001/jama.290.23.3122